ABSTRACT
The COVID-19 pandemic has challenged the medical world in many ways regarding diagnosis troubles and therapeutic options. In this paper, we will present three cases of patients from different age groups, in which we identified specific ways of evolution, from both clinically and laboratory data point of view. We used a critical evolution risk estimation calculator at admission and compared the results with the subsequent evolution of patients. From the analysis of the presented cases, we found persistent organic damage that will require their long-term follow-up. © 2020, Amaltea Medical Publishing House. All rights reserved.
ABSTRACT
Background: Although rare, there is increasing incidence of myocarditis in young adult males who receive the second dose of the COVID-19 mRNA vaccine. We present a rare case of myocarditis in a young female following the initial dose. Case: A 20-year-old female presented with progressive pleuritic chest pain and fever. Past medical history was significant for depression and COVID-19 infection 5 months prior to admission. She received the first dose of the Moderna mRNA vaccine one week prior to admission. She had elevated D-dimer, erythrocyte sedimentation rate (ESR), and troponin levels. Electrocardiogram showed PR depression. Echocardiogram, respiratory viral panels, and cultures were normal. Decision-making: Due to persistent worsening chest pain, she underwent cardiac magnetic resonance imaging (CMRI), which was consistent with myocarditis. She was treated with supportive care and her condition improved. Given the temporal relationship between vaccine administration and symptom onset, as well as negative viral testing, it was determined that the Moderna vaccine was likely the culprit. Conclusion: COVID-19 vaccine-induced myocarditis is becoming a more recognized entity, however other more common etiologies should be first ruled out. Nonetheless, the benefits of immunization against COVID-19 outweigh the risks of vaccine-induced myocarditis. [Formula presented]